Von Eschenbach in ‘07?
This article was originally published in The Gray Sheet
Executive Summary
Senate HELP Committee staffer says it is "highly unlikely" that Acting FDA Commissioner Andrew von Eschenbach, MD, will be confirmed as permanent commissioner this year. The confirmation hold initiated by Sens. Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) stems from political wrangling over the agency's handling of emergency contraceptive drug, Plan B (1"The Gray Sheet" April 3, 2006, p. 13)...
You may also be interested in...
Plan B Backlash Blocks FDA Commissioner Nomination, Take Two
FDA will not have a permanent commissioner until a decision is announced on over-the-counter sales of Barr's emergency contraceptive Plan B, if a hold by Senate Democrats is respected
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.